LEADER 05858nam 2201573z- 450 001 9910566471803321 005 20231214133446.0 035 $a(CKB)5680000000037662 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81021 035 $a(EXLCZ)995680000000037662 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aEndothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (368 p.) 311 $a3-0365-3036-3 311 $a3-0365-3037-1 330 $aDear colleagues, This Special Issue, ?Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches?, focuses on the pathophysiology of endothelial dysfunction, new biomarkers for endothelial dysfunction related to cardiovascular disorders or tumors, and novel therapeutic approaches for endothelial dysfunctions. Vascular endothelium is an active tissue and plays a crucial role in the maintenance of vascular homeostasis. Chronic exposure to risk factors, such as hypertension, high cholesterolemia, or oxidative stress, induces endothelial dysfunctions and results in a loss of endothelial integrity, smooth muscle cell proliferation, and macrophage recruitment. The pathophysiology of endothelial dysfunction (ED) is complex and multi-factorial factors are involved, such as oxidative stress or chronic inflammation. The primary prevention of cardiovascular risk factors and endothelial dysfunctions, as well as the early detection of or molecular imaging techniques for endothelial dysfunction, helps to prevent the development of cardiovascular disorders. Novel therapeutic approaches or drug delivery systems for endothelial dysfunctions have had promising beneficial effects in preclinical or clinical levels by affecting the progression of atherosclerotic changes, tumor angiogenesis, and host?immune reactions near tumor environments. 517 $aEndothelial Dysfunction 606 $aTechnology: general issues$2bicssc 606 $aBiotechnology$2bicssc 610 $aendothelial cells 610 $aoxidative stress 610 $ainflammageing 610 $aendothelial dysfunction 610 $aaldehyde dehydrogenase-2 610 $acardiovascular disease 610 $aneurovascular disease 610 $avascular inflammation 610 $aAPE1/Ref-1 610 $acardiovascular diseases 610 $asubcellular localization 610 $aserological biomarkers 610 $aatherosclerosis 610 $aaerobic exercise 610 $aPCSK9 610 $aLOX-1 610 $ainsulin resistance 610 $amacrophage polarity 610 $aserum ?-glutamyltransferase 610 $aessential hypertension 610 $acardiovascular risk factors 610 $aangiogenesis 610 $anargenicin A1 610 $acompound 9 610 $aVEGF 610 $aVEGFR2 610 $aHIF-1? 610 $aelectronegative low-density lipoprotein 610 $aLDL(-) 610 $aL5 LDL 610 $aoxidized LDL 610 $aoxLDL 610 $aADMA 610 $aarginine 610 $aarginine paradox 610 $aBH4 610 $ablood pressure 610 $aCOVID-19 610 $adietary supplements 610 $aendothelium 610 $aeNOS uncoupling 610 $aheart failure 610 $ahypertension 610 $aL-arginine 610 $amyocardial infarction 610 $aNADPH 610 $anitric oxide 610 $aperipheral artery disease 610 $aApoE knockout mouse 610 $aatorvastatin 610 $aVCAM-1 610 $agalectin-3 610 $aneutrophil/lymphocyte ratio 610 $aelectronegative LDL 610 $aLDL(?) 610 $alectin-like oxLDL receptor-1 610 $adyslipidemia 610 $achronic venous insufficiency 610 $aprolyl oligopeptidase (POP) 610 $ainflammation 610 $aendothelial disfunction 610 $alung disease 610 $aendothelial to mesenchymal transition 610 $apulmonary hypertension 610 $apulmonary fibrosis 610 $ametformin 610 $adiabetes 610 $aCV risk 610 $ahyperglycemia 610 $aglycated lipoproteins 610 $aglycated LDL 610 $aglycated HDL 610 $aendothelial cell dysfunction 610 $amolecular mechanisms 610 $aepigenetic factors 610 $atherapeutic approaches 610 $avasoactive factors 610 $aEndoMT 610 $aTGF-? 610 $aepigenetics 610 $aendothelial cell 610 $aglycolysis 610 $ametabolism 610 $apathological angiogenesis 610 $atumor microenvironment 610 $aMRI (magnetic resonance imaging) 610 $ahigh-fat diets 610 $aplaque burden 610 $alow-level laser therapy 610 $aphototherapy 610 $avascular disease 610 $ahealing 610 $aischemia 610 $avascular calcification 610 $achronic kidney disease 610 $aCKD 610 $auremic toxins 610 $ahyperphosphatemia 610 $avascular smooth muscle cells 610 $aVSMCs 610 $amacrophages 615 7$aTechnology: general issues 615 7$aBiotechnology 700 $aJeon$b Byeong Hwa$4edt$01319556 702 $aJeon$b Byeong Hwa$4oth 906 $aBOOK 912 $a9910566471803321 996 $aEndothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches$93033962 997 $aUNINA